T. Rowe Price Investment Management
IMNM icon

T. Rowe Price Investment Management’s Immunome IMNM Stock Holding History

T. Rowe Price Investment Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$358M Buy
16,364,011
+2,942,024
+22% +$65.5M 0.25% 99
2025
Q4 		$288M Buy
13,421,987
+5,003,824
+59% +$87.8M 0.18% 132
2025
Q3 		$98.6M Buy
8,418,163
+142,906
+2% +$1.42M 0.06% 272
2025
Q2 		$77M Buy
8,275,257
+720,663
+10% +$5.91M 0.05% 324
2025
Q1 		$50.8M Buy
7,554,594
+2,054,640
+37% +$19.7M 0.03% 389
2024
Q4 		$58.4M Sell
5,499,954
-262,059
-5% -$3.17M 0.04% 385
2024
Q3 		$84.2M Buy
5,762,013
+1,883,418
+49% +$26.8M 0.05% 327
2024
Q2 		$46.9M Buy
3,878,595
+2,362,141
+156% +$37M 0.03% 395
2024
Q1 		$37.4M Buy
+1,516,454
New +$30.8M 0.02% 440

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management's IMNM Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its Immunome (IMNM) stake by 22% in Q1 2026, buying an estimated $65.5M and bringing the position to 16,364,011 shares worth $358M. The position accounts for 0.25% of the portfolio, ranked #99.

T. Rowe Price Investment Management first reported a position in IMNM in Q1 2024 and has held it in 9 quarters since. 201 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • T. Rowe Price Investment Management held 16,364,011 shares of Immunome worth $358M as of Q1 2026.
  • T. Rowe Price Investment Management bought 2,942,024 Immunome shares in Q1 2026, an estimated $65.5M.
  • Immunome made up 0.25% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #99 holding.
  • T. Rowe Price Investment Management first reported a position in Immunome in Q1 2024 and has held it in 9 quarters since.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.